Tissue Regenix Group PLC Issue of equity and total voting rights (0248E)
February 04 2015 - 5:59AM
UK Regulatory
TIDMTRX
RNS Number : 0248E
Tissue Regenix Group PLC
04 February 2015
Tissue Regenix Group plc
Issue of equity and total voting rights
YORK, 04 February 2015 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Group"), the international regenerative
medical devices company, announces that it has today issued and
allotted 26,664 ordinary shares of 0.5p each in the Company,
following an exercise of options which were granted under the
Company's Enterprise Management Incentive scheme.
The 26,664 new ordinary shares will rank pari passu with the
existing ordinary shares and application will be made for these new
ordinary shares to be admitted to trading on AIM. It is expected
that Admission will occur at 8:00 a.m. on 10th February 2015.
Total Voting Rights
Following the issue of the 26,664 new ordinary shares, the
Company will have a total of 654,149,695 ordinary shares of 0.5p
each in issue. The above figure may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the FSA's Disclosure and Transparency Rules.
ENDS
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Tulchan Communications: +44 207 353 4200
Tom Buchanan
Victoria Huxster
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAEALESPSEFF
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024